Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) shares reached a new 52-week low on Monday . The stock traded as low as C$0.37 and last traded at C$0.39, with a volume of 65380 shares traded. The stock had previously closed at C$0.40.
Medicenna Therapeutics Stock Down 2.5%
The company’s 50 day moving average price is C$0.48 and its two-hundred day moving average price is C$0.70. The company has a current ratio of 1.52, a quick ratio of 4.65 and a debt-to-equity ratio of 4.79. The firm has a market cap of C$35.54 million, a PE ratio of -1.75 and a beta of 2.96.
Medicenna Therapeutics (TSE:MDNA – Get Free Report) last announced its earnings results on Thursday, June 25th. The company reported C($0.05) EPS for the quarter. Medicenna Therapeutics had a negative return on equity of 219.30% and a negative net margin of 533,640.00%. On average, equities research analysts expect that Medicenna Therapeutics Corp. will post -0.37 EPS for the current fiscal year.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.
Featured Articles
- Five stocks we like better than Medicenna Therapeutics
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
- KBR Insiders Are Buying While the Market Misreads Its Spinoff
- Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
- Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
